pertuzumab/trastuzumab with hyaluronidase (Phesgo)

Indications

• treatment of HER2+ breast cancer
  • initially used in combination with chemotherapy

* for use with an FDA-approved companion diagnostic test

Dosage

• subcutaneous injection

* can be administered at home by a qualified health care professional once chemotherapy regimen has been completed

Adverse effects

• alopecia, nausea, diarrhea, anemia, asthenia

* boxed warnings

• risk of heart failure, fetal harm & lung toxicity

Drug interactions

• Phesgocan worsen chemotherapy induced neutropenia

Mechanism of action

• pertuzumab & trastuzumab bind to sites on HER2 & disrupt signaling

More general terms

• antineoplastic combination (combination chemotherapy)

Components

• pertuzumab (Perjeta)
• trastuzumab (Herceptin, Herzuma, CT-P6)